Dr. Stephen Levine Reflects on 40 Years in Gender Medicine. - Original Rebels Series (#21
10 July 2025
With Stephen B. Levine
Global
Dr. Stephen Levine co-founded one of America's first gender identity clinics in 1974 and chaired a WPATH Standards of Care committee before leaving the organisation when advocacy displaced science. His first-hand account of how peer review gave way to institutional pressure maps directly onto the evidence gaps that European health authorities — from NICE to the Swedish Agency for Health Technology Assessment — have since been forced to acknowledge. The episode offers a clinician's-eye view of the conditions that produced the guidelines now being dismantled across Europe.
Dr. Stephen B. Levine has been inside gender medicine since 1974, when he co-founded one of the first gender identity clinics in the United States at Case Western Reserve University School of Medicine. He later chaired the fifth Standards of Care committee for what would become the World Professional Association for Transgender Health, giving him an unmatched insider's view of how clinical guidance in this field is constructed — and how it can fail. He left WPATH in 2002, long before the current public controversy, after concluding that advocacy had displaced scientific inquiry within the organisation. What Levine describes is a cultural shift in professional medicine with direct consequences for clinical practice across Europe. WPATH's Standards of Care have long been cited by clinicians and policymakers on the continent as the international benchmark for gender medicine. Yet Levine recounts how dissenting voices were systematically marginalised — with booing replacing peer review at professional conferences. For European regulators, the question this raises is pointed: if the primary international guideline was shaped more by institutional advocacy than by evidence, what are the downstream consequences for the national protocols built upon it? Among the specific claims Levine examines is the widely circulated figure that regret rates following medical gender transition are as low as two percent. He identifies this as a myth with significant policy consequences. The critique is not his alone. Systematic reviews by England's National Institute for Health and Care Excellence, by the Swedish Agency for Health Technology Assessment, and by Finland's Council for Choices in Health Care have all found the evidence base for medical gender transition in adolescents to be weak, inconsistent, and too short-term to sustain the clinical confidence with which the pathway has been applied. Levine argues that psychiatry once approached gender dysphoria with genuine curiosity — exploring its causes, its relationship to other psychological conditions, and whether different presentations warranted different clinical responses. That curiosity, he suggests, was replaced by a culture of compliance in which clinicians face professional consequences for doing what good medicine demands: asking questions. The Cass Review, published in England in 2024, reached a structurally similar conclusion, finding that ideological capture had produced a therapeutic monoculture in which psychological assessment and watchful waiting were treated as harmful rather than prudent. Levine's insistence on the phrase "we don't know" may appear to be a concession, but he frames it as the precondition for honest medicine. European health authorities have increasingly reached the same position. Sweden, Finland, Denmark, Norway, and England have all moved to restrict or substantially limit the medical pathway for gender-dysphoric young people, each citing an insufficient evidence base. What this episode contributes is a first-hand account of how the field arrived at a state of false certainty — and why recovering genuine clinical judgment will require both institutional courage and a willingness to hold open questions open.
